A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R. Glucagon-like peptide 1 receptor agonists (GLP-1RAs), widely used medications for managing type 2 diabetes and obesity, have recently gained attention for their rising popularity as weight loss drugs. However, these medications have been associated with behavioral […]
Source link